Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Meier

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2020
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTSElena Tsourdi, M Carola Zillikens, Christian Meier, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
BMC Pulmonary Medicine|December 29, 2017
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access studyVallerie V McLaughlin, Pavel Jansa, Jens E Nielsen-Kudsk, et al.
Swiss Medical Weekly|April 10, 2026
Endocrine care of transgender and gender-diverse adults: Swiss recommendationsHüseyin Cihan, Barbara Bischofberger-Baumann, Julie Bucher, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Respiratory Medicine|February 4, 2021
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registryHossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
Respiratory Medicine|January 10, 2021
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registryMarius M Hoeper, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2020
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTSElena Tsourdi, M Carola Zillikens, Christian Meier, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
BMC Pulmonary Medicine|December 29, 2017
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access studyVallerie V McLaughlin, Pavel Jansa, Jens E Nielsen-Kudsk, et al.
Swiss Medical Weekly|April 10, 2026
Endocrine care of transgender and gender-diverse adults: Swiss recommendationsHüseyin Cihan, Barbara Bischofberger-Baumann, Julie Bucher, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Respiratory Medicine|February 4, 2021
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registryHossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
Respiratory Medicine|January 10, 2021
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registryMarius M Hoeper, Miguel-Angel Gomez Sanchez, Marc Humbert, et al.
Pageof 16